



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger

Judith U. Kim
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Laura A. Vogel
Bryan S. Wade
Aaron L. Schwartz
Bashir M.S. Ali
Shannon A. Carroll

Wesley W. Jones
Matthew E. Kelley
Michelle K. Holoubek*
Marsha A. Rose*
W. Blake Coblenz*
James J. Pohl*
John T. Haran*
Mark W. Rygiel

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford

Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey Mills
Danielle L. Letting
Lori Brandes

Of Counsel
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

December 30, 2005

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8538
INTERNET ADDRESS:
DBANOWIT@SKGF.COM

Art Unit 1615

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/786,561; Filed: February 26, 2004
For: **Microbicidal Compositions and Method of Use**
Inventors: CAMUS-BABLON *et al.*
Our Ref: 2252.0010001/DRB/KPQ

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A listing cited U.S. and Foreign documents AJ1-AM1, AA2-AK2, AA3-AK3, AA4-AK4, AA5-AK5 and AA6-AC6 (3 pages);
3. Form PTO/SB/08B listing Non Patent reference documents AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10-T10, AR11-AT11, AR12-AT12, AR13-AT13, AR14-AT14, AR15-AT15, AR16-AT16, AR17-AT17, AR18-AT18 and AR19-AS19 (6 pages); and
4. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 30, 2005
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Donald R. Banowit
Attorney for Applicants
Registration No. 42,289

DRB/lna
Enclosures

480819_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CAMUS-BABLON *et al.*

Appl. No.: 10/786,561

Filed: February 26, 2004

For: **Microbicidal Compositions and
Method of Use**

Confirmation No.: 1824

Art Unit: 1615

Examiner: Page, Thurman K.

Atty. Docket: 2252.0010001/DRB/KPQ

**First Supplemental Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08A and Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on January 3, 2005, in connection with the above-captioned application.

Copies of documents **AL1**, **AM1**, and **AT1-AS19** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents, documents **AJ1-AC6**, cited on the attached Form PTO/SB/08A are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **AR2**, **AR3**, **AT5**, **AR6**, **AS6**, **AT6**, **AR7**, **AS7**, **AR8**, **AS9**, **AR10**, **AR11**,

AS12, AT12, AR13, AS13, AR14, AS14, AR15, AT15, AR17, AS17, AT17, and AT18

cited on Form PTO/SB/08B:

Documents **AR2, AR3, AT5, AR6, AS6, AT6, AR7, AS7, AR8, AS9, AR10, AR11, AS12, AT12, AR13, AS13, AR14, AS14, AR15, AT15, AR17, AS17, AT17, and AT18** are written in foreign languages. English-language abstracts/summaries of these documents are located within said documents.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed Form PTO/SB/08A and Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Donald R. Banowit
Attorney for Applicants
Registration No. 42,289

Date: 12-30-05

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

453374_1.DOC



FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/786,561
				Filing Date	February 26, 2004
				First Named Inventor	Florence Camus-Bablon
				Art Unit	1615
				Examiner Name	Page, Thurman K.
Sheet	1	of	3	Attorney Docket Number	2252.0010001/DRB/KPQ

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
	AJ1	2,149,240	02/28/1939	Crossley	
	AK1	2,330,846	10/05/1943	Sander	
	AA2	2,436,184	02/17/1948	Stillman and Scott	
	AB2	2,467,884	04/19/1949	Elias	
	AC2	2,541,103	01/13/1951	Sander	
	AD2	2,623,839	12/30/1952	Taub	
	AE2	2,623,841	12/30/1952	Taub	
	AF2	3,062,715	11/06/1962	Reese <i>et al.</i>	
	AG2	3,067,743	12/11/1962	Merton and Blood	
	AH2	3,108,043	10/22/1963	Millman <i>et al.</i>	
	AI2	3,174,900	03/23/1965	Wyant	
	AJ2	3,244,589	04/05/1966	Sunan and McCowan	
	AK2	3,640,741	02/08/1972	Etes	
	AA3	3,826,828	07/30/1974	Morel	
	AB3	3,887,699	06/03/1975	Yolles	
	AC3	3,916,898	11/04/1975	Robinson	
	AD3	3,989,816	11/02/1976	Rajadhyaksha	
	AE3	4,011,312	03/08/1977	Reuter and Tsuk	
	AF3	4,017,641	04/12/1977	DiGiulio	
	AG3	4,093,730	06/06/1978	Butti and Gazzani	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AL1	WO 93/25209 A1	12/23/1993	Fabulon RG Kozmetikai KFT.		
	AM1	DE 198 03 193 C1	07/15/1999	Dr. August Wolff G.m.b.H. und Co..		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

U.S. PATENT DOCUMENTSFOREIGN PATENT DOCUMENTS

453260 1.DOC


**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Application Number				10/786,561	
Filing Date				February 26, 2004	
First Named Inventor				Florence Camus-Bablon	
Art Unit				1615	
Examiner Name				Page, Thurman K.	
Attorney Docket Number				2252.0010001/DRB/KPQ	
Sheet	1	of	6		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		T ²
	AT1	Abrams, B.B., <i>et al.</i> , "Ciclopirox Olamine: A Hydroxypyridon Antifungal Agent," <i>Clin. Derm.</i> 9: 471-477, Elsevier Science Publishing, Inc. (1992)		
	AR2	Alpermann, H.G. and Schültz, E., "Zur Pharmakologie und Toxikologie von Ciclopiroxolamin (Studies on the Pharmacology and Toxicology of Ciclopiroxolamine)," <i>Arzneim.-Forsch./Drug Res.</i> 31 (8A):1328-1332, Editio Cantor (1981)		
	AS2	Baron, S., <i>et al.</i> , "Practical Prevention of Vaginal and Rectal Transmission of HIV by Adapting the Oral Defense: Use of Commercial Lubricants," <i>AIDS Research and Human Retroviruses</i> 17: 997-1002, Mary Ann Liebert, Inc. (2001)		
	AT2	Braga, P.C., <i>et al.</i> , "Effects of Subinhibitory Concentrations of Ciclopirox on the Adherence of Candida albicans to Human Buccal and Vaginal Epithelial Cells," <i>Arzneim.-Forsch./Drug Res.</i> 42: 1368-71, Editio Cantor (1992)		
	AR3	Bucciero, A., <i>et al.</i> , "La ciclopiroxolamine nel trattamento topico delle micosi vaginali (Ciclopiroxolamine in the topical treatment of vaginal mycoses)," <i>Minerva Ginecol.</i> 41:283-6, Index Medicus, Excerpta Medica (1989)		
	AS3	Carl, W. and Emrich, L.S., "Management of oral mucositis during local radiation and systemic chemotherapy: A study of 98 patients," <i>J. Prosthetic Dentistry</i> 66: 361-369, Mosby-Year Book, Inc. (1991)		
	AT3	Clement, P.M., <i>et al.</i> , "The Antifungal Drug Ciclopirox Inhibits Deoxyhypusine and Proline Hydroxylation, Endothelial Cell Growth and Angiogenesis <i>In Vitro</i> ," <i>Int. J. Cancer</i> 100: 491-8, Wiley-Liss, Inc. (Published online June 2002)		
	AR4	Clement, P.M., <i>et al.</i> , "A Candidate Drug for Chemoprevention of Cervical Cancer: Antiproliferative Effects of the Fungicide Ciclopirox in the Cervical Cancer Line SiHa," Presented at the <i>Society of Gynecologic Oncologists 34th Annual Meeting on Women's Cancer</i> , New Orleans, LA, Jan. 31-Feb. 4, 2003		
	AS4	Coppi, G., <i>et al.</i> , "Pharmacokinetics of Ciclopirox Olamine after Vaginal Application to Rabbits and Patients," <i>J. Chemother.</i> 5: 302-6, Firenze E.I.F.T. Srl (1993)		
	AT4	Coppi, G. and Silingardi, S., "HPLC Method for Pharmacokinetic Studies on Ciclopirox Olamine in Rabbits after Intravenous and Intravaginal Administrations," <i>IL Farmaco.</i> 47(5 Supl):779-86, Presented at the <i>IV Convegno su Recenti Sviluppi ed Applicazioni nell' Analisi Farmaceutica</i> , Bologna, 1991, Società Chimica Italiana (1992)		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/786,561
				Filing Date	February 26, 2004
				First Named Inventor	Florence Camus-Bablon
				Art Unit	1615
				Examiner Name	Page, Thurman K.
Sheet	2	of	6	Attorney Docket Number	2252.0010001/DRB/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AR5	Cosmetic Ingredient Review Panel, "Final Report on the Safety Assessment of Bisabolol," <i>Intl. J. Toxicol.</i> 18(Suppl. 3): 33-40, Taylor & Francis (1999)	
	AS5	Critchfield, J.W., <i>et al.</i> , "Inhibition of HIV Activation in Latently Infected Cells by Flavonoid Compounds," <i>AIDS Res. Hum. Retroviruses</i> 12: 39-46, Mary Ann Liebert, Inc. (1996)	
	AT5	Czaika, V., <i>et al.</i> , "Resistenzbestimmungen bei Erregern chronisch rezidivierender Vaginalcandidosen als Voraussetzung für eine effektive Therapie (Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy)," <i>Mycoses</i> 43 (Suppl 2):45-50, Blackwell Wissenschafts-Verlag GmbH (2000)	
	AR6	Damianov, L., <i>et al.</i> , "Treatment of Acute Mycotic Colpitis with Ciclopiroxolamine of Women Using Combined Oral Contraceptives," <i>Akush. Ginekol. (Obstetrics & Gynecology)</i> 36:32-33, Meditsina I Fizkultura (1997)	
	AS6	Garcia Figueroa R.G., <i>et al.</i> , "Eficacia y seguridad de ciclopirox olamina en crema vaginal al 1% contra terconazol en crema vaginal al 0.8% en el tratamiento de candidiasis genital (Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis)," <i>Ginecol. Obstet. Mex.</i> 68: 154-9, Asociacion Mexicana de Ginecologia y Obstetricia (2000)	
	AT6	Gehse M., <i>et al.</i> , Über die effektive Hornschichthemmtiefe von Ciclopiroxolamin und Naftifin in Abhängigkeit von der galensichen Zubereitung (On the Effective Dimension of Inhibition of Ciclopiroxolamine and Naftifine in the Horny Layer with Regard to the Galenic Preparation," <i>Mykosen</i> 30: 322-325, Grosse Verlag GmbH (1987)	
	AR7	Giannoni M., <i>et al.</i> , "Studio clinico sulla ciclopiroxolamina versus clotrimazolo nel trattamento delle vulvovaginiti micotiche (Clinical study of ciclopiroxolamine vs clotrimazole in the treatment of vulvovaginal candidiasis)," <i>Minerva Med.</i> 81: 555-9, Edizioni Minerva Medica (1990)	
	AS7	Grassi, A., <i>et al.</i> , "Studio di tollerabilità ed efficacia di preparati dermocosmetici ad azione lenitiva nella dermatite atopica infantile (Study of tolerance and efficacy of cosmetic preparations with lenitive action in atopic dermatitis in children)," <i>Clin. Ter.</i> 151: 77-80, Excerpta Medica (2000)	
	AT7	Gupta, A.K., "Ciclopirox: an overview," <i>Intl. J. Dermatol.</i> 40:305-10, Blackwell Science Ltd. (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/786,561
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	February 26, 2004
				First Named Inventor	Florence Camus-Bablon
				Art Unit	1615
				Examiner Name	Page, Thurman K.
Sheet	3	of	6	Attorney Docket Number	2252.0010001/DRB/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AR8	Hahn, B. and Holzl, J., "Resorption, Verteilung und Metabolismus von [¹⁴ C]-Levomenol in der Haut (Absorption, Distribution and Metabolism of [¹⁴ C]-Levomenol in the Skin)," <i>Arzneim.-Forsch./Durg Res.</i> 37: 716-720, Marcel Dekker, Inc. (1987)	
	AS8	Hahn, G.S., "Anti-irritants for Sensory Irritation," in <i>Handbook of Cosmetic Science and Technology</i> , Barol, A.O., et al., eds., Marcel Dekker, New York, pp. 285-287 (2001)	
	AT8	Hernandez-Ceruelos A., et al., "Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methanesulfonate in mouse bone marrow," <i>Toxicol. Lett.</i> 135: 103-110, Elsevier Science Ireland Ltd. (September 2002)	
	AR9	Jager, S.U., et al., "Allergic contact dermatitis from ciclopiroxolamine?," <i>Contact Dermatitis.</i> 33:349-50, Munksgaard (1995)	
	AS9	Jasonnni, V.M., et al., "Studio clinico contrallato della ciclopiroxolamina nelle candidosi vaginali (Controlled clinical study of cyclopyroxolamine in vaginal candidiasis)," <i>Minerva Ginecol.</i> 41:417-419, Index Medicus, Excerpta Medica (1989)	
	AT9	Jue, S.G., et al., "Ciclopirox Olamine 1% Cream: A Preliminary Review of Its Antimicrobial Activity and Therapeutic Use," <i>Drugs</i> 29:330-341, ADIS Press Limited (1985)	
	AR10	Kellner, H.M., et al., "Untersuchungen zur Pharmakokinetik und Biotransformation des Antimykotikums Ciclopiroxolamine bei Tieren und beim Menschen nach topischer und systemischer Anwendung (Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration)," <i>Arzneim.-Forsch./Drug. Res.</i> 31: 1337-1353, Editio Cantor (1981)	
	AS10	Korting, H.C. and Grundmann-Kollmann, M., "The hydroxypyridones: a class of antimycotics of its own (Die Hydroxypyridone als eigenständige Antimykotikaklasse)," <i>Mycoses</i> 40:243-247, Blackwell Publishing (1997)	
	AT10	Linden, T., et al., "The antimycotic ciclopirox olamine induces HIV-1α statbility, VEGF expression, and angiogenesis," <i>FASEB J.</i> 17:761-763, Federation or American Societies of Experimental Biology (April 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/786,561
				Filing Date	February 26, 2004
				First Named Inventor	Florence Camus-Bablon
				Art Unit	1615
				Examiner Name	Page, Thurman K.
Sheet	4	of	6	Attorney Docket Number	2252.0010001/DRB/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AR11	Lohaus G. and Dittmar, W., "Zur Chemie von antimikrobiell wirksamen 1-Hydroxy-2-pyridonen (The Chemistry of antimicrobially Active 1-Hydroxy-2-pyridones)," <i>Arzneim.-Forsch./Drug Res.</i> 31:1311-1316, Editio Cantor (1981)	
	AS11	Lu, T., <i>et al.</i> , "Antimycobacterial Matriacaria Esters and Lactones from Astereae Species," <i>Planta Medica</i> 64: 665-667, Georg Thieme Verlag Stuttgart (1998)	
	AT11	Manzardo, S., <i>et al.</i> , "Local Tolerance of a New Ciclopirox Olamine Vaginal Preparation in Rats and Rabbits," <i>J. Chemother.</i> 5:307-312, Firenze E.I.F.T. Srl (1993)	
	AR12	Marino, M., <i>et al.</i> , "Impedance measurements to study the antimicrobial activity of essential oils from <i>Lamiaceae</i> and <i>Compositae</i> ," <i>Int. J. Food Microbiol.</i> 67:187-195, Elsevier Science B.V. (2001)	
	AS12	Miyamoto, M., <i>et al.</i> , "Teratological Studies of 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296) in Mice and Rats," <i>Oyo Yakur (Pharmacometrics)</i> 9:97-108, Kindai igakusha (1975)	
	AT12	Mizukami, K., <i>et al.</i> , "Influence of the Consecutive Dermal Application of 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone ethanolamine salt (Hoe 296) to Beagle Dogs for 6 Months," <i>Oyo Yakur (Pharmacometrics)</i> 9: 83-95, Kindai igakusha (1975)	
	AR13	Mizukami, K., <i>et al.</i> , "Subacute Toxicity of 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone ethanolamine salt (Hoe 296) in Rats," <i>Oyo Yakur (Pharmacometrics)</i> 9: 67-81, Kindai igakusha (1975)	
	AS13	Nencioni, T., <i>et al.</i> , "Vulvovaginiti Micotiche E Ciclopiroxolamina Per Via Topica (Mycological vulvovaginitis and topical ciclopiroxolamine)," <i>Minerva Ginecol.</i> 40:719-22, Index Medicus, Excerpta Medica (1988)	
	AT13	Niewerth, M., <i>et al.</i> , "Antimicrobial susceptibility testing of dermatophytes--comparison of the agar macrodilution and broth microdilution tests," <i>Chemother.</i> 44: 31-5, S. Karger (1998)	
	AR14	Nissen, H.P., <i>et al.</i> , "Profilometrie, eine Methode zur Beurteilung der therapeutischen Wirksamkeit von Kamillosan®-Salbe* (Profilometry. A Method to Evaluate the Therapeutic Efficacy of Kamillosan® Ointment*)," <i>Z. Hautkr.</i> 63: 184-190, Grosse Verlag GmbH (1988)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/786,561
				Filing Date	February 26, 2004
				First Named Inventor	Florence Camus-Bablon
				Art Unit	1615
				Examiner Name	Page, Thurman K.
Sheet	5	of	6	Attorney Docket Number	2252.0010001/DRB/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AS14	Novachkov, V., <i>et al.</i> , "Treatment of Acute Colpitis Mycotica with Ciclopiroxolamine/Dafnegin-CSC in Patients in the 10-th Month of Pregnancy," <i>Akush. Ginek. 38:54-55, Meditsina I Fizkultura</i> (1999)	
	AT14	Patzelt-Wenczler, R. and Ponce-Poschl, E., "Proof of Efficacy of Kamillosan® Cream in Atopic Eczema," <i>Eur. J. Med. Res. 19:171-175, I. Holzapfel Publishers</i> (2000)	
	AR15	Peil, H.G., "Offene Studie zur Wirksamkeit und Vertraglichkeit von Ciclopiroxolamin bei vulvovaginaler Candidose (Open Clinical Study on the Efficacy and Tolerance of Ciclopiroxolamine in Vulvovaginal Candidosis)," <i>Arzneim.-Forsch./Drug Res. 31:1366-1368, Editio Cantor</i> (1981)	
	AS15	Roberts, E., "Chamomile flower, German," in <i>The Complete German Commission E Monographs-Therapeutic Guide to Herbal Medicines</i> , Blumenthal, M., <i>et al.</i> , eds., American Botanical Council, Boston, MA, p. 107 (1998)	
	AT15	Rustichelli, S., <i>et al.</i> , "Ciclopiroxolamina considerazioni preliminari sull'impiego di un nuovo antimicotico non imidazolico nella patologia infettiva genitale (Cyclopiroxolamine: preliminary remarks on the use of a new non-imidazole antimycotic in genital infections)," <i>Minerva Ginecol. 39:793-6, Index Medicus, Excerpta Medica</i> (1987)	
	AR16	Safayhi, H., <i>et al.</i> , "Chamazulene: An Antioxidant-Type Inhibitor of Leukotriene B ₄ Formation," <i>Planta Med. 60: 410-413, Georg Thieme Verlag Stuttgart</i> (1994)	
	AS16	Salaman, I., "Chamomile: A Medicinal Plant," <i>Herb Spice Med Plant Digest 10:1-4, University of Massachusetts Cooperative Extension System</i> (1992)	
	AT16	Stanzl, K. and Vollhardt, J., "The Case of Alpha-Bisabolol," in <i>Handbook of Cosmetic Science and Technology</i> , Barol, A.O., <i>et al.</i> , eds., Marcel Dekker, New York, pp. 277-284 (2001)	
	AR17	Suganda, A.G., <i>et al.</i> , "Effets Inhibiteurs de Quelques Extraits Bruts et Semi Purifiés de Plantes Indigènes Françaises sur la Multiplication de L'herpesvirus Humain 1 et du Poliovirus Humain 2 en Culture Cellulaire," <i>J. Natural Plants 46:626-632, The American Society of Pharmacognosy and The Lloyd Library and Museum</i> (1983)	
	AS17	Szalontai, M., <i>et al.</i> , "Adatok a Matricaria chamomilla L. biológiai aktiv komponenseinek antifungális hatásához (Data on the antifungal effect of the biologically active components of matricaria chamomilla L.)," <i>Acta Pharmaceutica Hungarica 46: 232-247, Magyar gyogyszereszeti tarsasag</i> (1976)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/786,561
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	February 26, 2004
				First Named Inventor	Florence Camus-Bablon
				Art Unit	1615
				Examiner Name	Page, Thurman K.
Sheet	6	of	6	Attorney Docket Number	2252.0010001/DRB/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	AT17	Tiets, H.-J., "Therapieproblem chronisch rezidivierende Vaginalmykose (Therapy problems in chronic recurrent vaginal mycosis)," <i>Ther Umsch.</i> 59:481-484, Verlag Hans Huber, Bern (September 2002)	
	AR18	Unknown, "In Vivo Studies of the Anti-Irritation Properties of Some Cosmetic Ingredients," in Handbook of Cosmetic Science and Technology, Barol, A.O., <i>et al.</i> , eds., Marcel Dekker, New York, pp. 265-270 (2001)	
	AS18	Unknown, "Flos Chamomillae," <i>WHO monographs on selected medicinal plants</i> 1:86-94, World Health Organizations (1999)	
	AT18	Wajnberg, E. and Wajnberg, A., "Doppelblind-Vergleichsstudie mit Ciclopiroxolamin- und Miconazol-Vaginalcreme bei vulvovaginaler Candidose (A Comparative Double Blind Trial with Vaginal Creams of Ciclopyroxolamine and Miconazole in Vulvovaginal Candidosis)," <i>Mykosen</i> 24:721-30, Grosse Verlag GmbH (1981)	
	AR19	International Search Report for International Application No. PCT/US04/05642, ISA, Alexandria, VA, mailed July 28, 2005	
	AS19	STNEasy/CAplus Database, Accession No. 1999:451505, English language abstract for DE 198 03 193 C1, document AM1	

453283_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.